Article 445: Academic Centers, CROs Share the Future

• According to Thomson CenterWatch , academic health centers' share of industry-sponsored clinical trials has slid to 25% in 2004, down from 80% of industry-sponsored clinical projects in 1991 and 60% in 1994.

Article 446: Bioequivalence Sector Breaks Out

• Once considered just a subset of the phase I market, bioequivalence has grown and evolved with its own set of unique challenges. If the market continues its impressive growth, bioequivalence trial work will mature into a healthy sector in its own right. As sponsor companies continue to want to alter their products in the dynamic branded vs. generic marketplace, the BE industry will be fed a continuous supply of project opportunities.

Article 447: Managing the Differences in Non-EU and EU Clinical Trial Conduct

• Managing a clinical trial that includes both European Union and non-EU countries is challenging.

Article 448: Eye on: Diseases of the Heart

• Worldwide, 17 million deaths are attributed to heart disease each year. CenterWatch has identified a pipeline of 25 drugs in development for heart disease.